CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$330.14

From 52W high−15.15%

Volume798450.00

Market cap$15.29B

P/E (TTM)312.9x

P/S (TTM)3.8x

Div yield—

Key dataNov 5, 2026

Open

$330.14

From 52W high

−15.15%

Volume

798450.00

Market cap

$15.29B

ValuationView details →

P/E (Fwd)

25.3x

EV/EBITDA

61.4x

P/E (TTM)

312.9x

RSI (14)

51.0

MomentumView details →

1D Return

−2.19%

YTD Return

+65.13%

SummaryUpdated Sep 1, 2026

Charles River Laboratories International, Inc. (NYSE:CRL) is a leading contract research organization founded in 1947 and headquartered in Wilmington, Massachusetts. The company went public in 2000 and has grown to become one of the world's largest providers of non-clinical drug development services to the pharmaceutical and biotechnology industries. Charles River operates globally across the United States, Europe, Canada, and the Asia Pacific region, serving as a critical partner in the drug discovery and development process by providing essential testing services, research models, and manufacturing solutions that help bring new medicines to market.

Ask drillr about CHARLES RIVER LABORATORIES INTERNATIONAL, INC. →

ValuationView details →

P/E (Fwd)

25.3x

P/E (TTM)

312.9x

EV/EBITDA

61.4x

EV/Sales

4.5x

P/S (TTM)

3.8x

P/B (TTM)

4.7x

ProfitabilityView details →

Gross Margin

32.90%

Net Margin

1.01%

EBITDA Margin

7.37%

ROE (TTM)

1.25%

ROA (TTM)

0.54%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

−1.16%

EPS YoY

+165.81%

FCF YoY

−26.49%

Revenue CAGR 3Y

+0.33%

EPS CAGR 3Y

—

EBITDA YoY

−43.23%

MomentumView details →

1D Return

−2.19%

YTD Return

+65.13%

1Y Return

+92.77%

RSI (14)

51.0

vs 50D SMA

+7.96%

vs 200D SMA

+47.01%

Capital & dividendView details →

Debt/Equity

0.88x

Current Ratio

1.41x

Quick Ratio

1.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.09

EPS Surprise

4.04%

Beats (12Q)

11/12

Next Q EPS Est

$3.33

Avg Surprise (4Q)

−80.75%

Rev Surprise

2.33%

Financials snapshotView financials →

Revenue (TTM)

3.98B

Net Income (TTM)

40.19M

Op. CF (TTM)

622.41M

Next earningsFeb 17, 2027 →

Latest newsMore news →

Charles River Laboratories shares rose after the company reported third-quarter results above estimates.1d ago

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. announced its third-quarter 2026 results.1d ago

Similar companies

ICON Public Limited CompanyICLR 金域医学603882.SH Revvity, Inc.RVTY Medpace Holdings, Inc.MEDP Joinn Laboratories(China)Co.,Ltd.06127.HK Exact Sciences CorporationEXAS Find similar companies →

Latest newsMore news →

Charles River Laboratories shares rose after the company reported third-quarter results above estimates.1d ago CHARLES RIVER LABORATORIES INTERNATIONAL, INC. announced its third-quarter 2026 results.1d ago LABCORP HOLDINGS INC. announced a research collaboration with the U.S. Food and Drug Administration and CHARLES RIVER LABORATORIES INTERNATIONAL, INC. to advance preclinical methods for evaluating medicines’ abuse potential.14d ago